This report is about Edinburgh Worldwide, a fund that invests in small, early-stage companies with breakthrough technologies—like space, quantum computing, and gene editing. The managers are optimistic about these frontier areas long-term, but admit the fund will swing more than the market and isn't for nervous investors. It returned 23% over the past year, yet lost 23% over five years—so recent gains follow a long weak stretch. Top holdings: Space Exploration Technologies (SpaceX, 20%), PsiQuantum (a private quantum-computing firm, 4.3%), and Xometry (a digital manufacturing marketplace, 3.8%). The report didn't list any buy or sell moves for the month.
Edinburgh Worldwide Investment Trust plc is a specialist global small-cap investment trust focused on listed and private companies at the forefront of technological innovation, aiming to achieve long-term capital growth through early-stage investment in companies with disruptive growth potential; th
As of 31/07/26: 1-year NAV return +23.3%, share price +21.2%, both outperforming the benchmark S&P Global Small Cap Index's +20.0%; however, 5-year NAV cumulative return stands at -23.4% versus the benchmark's +41.9%, still significantly lagging over the long term. The report does not disclose monthly returns, providing only rolling and fiscal-year measures; it also provides no stock-level attribution data.
| Measure | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|
| Share price | 21.2% | 51.8% | -29.0% | 146.3% |
| NAV | 23.3% | 30.3% | -23.4% | 134.0% |
| Benchmark | 20.0% | 40.3% | 41.9% | 148.2% |
Discrete fiscal-year performance (total return, GBP-denominated, dividends reinvested):
| Fiscal year (to 30/06) | 2021/22 | 2022/23 | 2023/24 | 2024/25 | 2025/26 |
|---|---|---|---|---|---|
| Share price | -51.5% | -18.9% | +4.4% | +17.5% | +67.9% |
| NAV | -42.4% | -11.4% | -7.1% | +12.8% | +63.5% |
| Benchmark | -11.3% | +8.2% | +10.5% | +4.5% | +33.0% |
[Optimistic (at the long-term strategy level), no stance on short-term market direction] The report contains only strategic statements with no current-month market outlook; the core stance is to continue backing early-stage companies at the frontier of technological innovation, explicitly accepting the volatility that comes with not tracking the index.
> "The portfolio does not seek to track the comparative index, hence a degree of volatility against companies index is inevitable."
> (i.e., the portfolio does not track the comparative index, so volatility relative to the index is unavoidable.)
This report discloses no month-over-month position openings, additions, reductions, or closures; the following is the static position structure as of 31/07/26. None of the companies listed in the report include buy/sell direction, only market-capitalization weightings.
Regional allocation (net current assets 2.4%):
| Region | Weight | Sub-item Detail |
|---|---|---|
| North America | 70.9% | — |
| Asia | 11.6% | China 3.3%, Taiwan 3.2%, Japan 3.0%, South Korea 1.3%, India 0.8% |
| Europe | 6.4% | Israel 3.2%, Switzerland 1.6%, others not listed |
| United Kingdom | 5.0% | — |
| Australasia | 2.3% | — |
| South America | 1.4% | — |
| Net current assets | 2.4% | — |
Top ten positions total 47.6% (the report gives no actions or commentary on any position; the following is weighting data only):
| # | Holding | % of Assets |
|---|---|---|
| 1 | Space Exploration Technologies | 19.9% |
| 2 | PsiQuantum | 4.3% |
| 3 | Xometry, Inc. | 3.8% |
| 4 | Twist Bioscience | 3.5% |
| 5 | Alnylam Pharmaceuticals | 2.8% |
| 6 | Axon Enterprise | 2.8% |
| 7 | Guardant Health | 2.7% |
| 8 | JFrog | 2.7% |
| 9 | Astera Labs | 2.6% |
| 10 | ASPEED Technology | 2.5% |
The industry distribution covers 23 industries in total; the report lists the top 20 by position size but provides no specific weightings, led in order by: Diversified Telecommunication Services, Software, Biotechnology, Semiconductors & Semiconductor Equipment, Health Care Providers & Services, Aerospace & Defense, Electronic Equipment, Instruments & Components, Trading Companies & Distributors, Electrical Equipment, Health Care Equipment & Supplies, Life Sciences Tools & Services, Machinery, IT Services, Pharmaceuticals, Real Estate Management, Consumer Finance, Consumer Staples Distribution & Retail, Technology Hardware, Metals & Mining, Diversified Consumer Services.
Total assets £891.79m, total borrowings £26.01m, ongoing charges 0.85%, zero dividend yield; net leverage of zero, no dividends paid, targeting pure capital appreciation.